Related to LabCorp Gains Rights to Merck & Co.’s IL-28B Polymorphism IP for HCV Therapy Predictive Test

• Merck & Co. Teams Up with India’s Serum Institute to Develop PCV Vaccine for Developing World
  
• Merck & Co. Seals Bispecific Antibody Collaboration with Zymeworks
  
• Merck & Co. and BGI Ink Deal Focused on Biomarkers and Genomic Technologies
  
• Genotyping HCV Patients for HLA-C and IL28B Improves Ability to Predict Treatment Response
  
• FKD Therapies Acquires Exclusive License to Merck & Co.’s Gene Therapy Portfolio
  
• Ezose, Merck & Co. Ink Diabetes Biomarker Deal
  
• Merck & Co. Axes Alzheimer Deal with Acumen, Nabs Exelixis’ PI3K-Delta Program
  
• Merck & Co. Licenses Protein Sciences’ Insect Cell Vaccine Production Platform
  
• Codexis, Merck & Co. Develop Prototype Enzyme-Based Method for Producing Boceprevir
  
• VC Firm Flagship Ventures Joins a Merck Fund in Launching Biotech Startups
  
• Merck & Co. Pays Endocyte $120M for Phase III Folate Receptor-Targeting Anticancer Drug
  
• Merck & Co. Partners with Trevena to Identify Biased GPCR Receptor Ligands
  
• XDx, LabCorp to Develop Lupus Flare Predictor Test
  
• Electronics Giant Samsung Makes First Big Biotech Play
  
• Merck and Luminex Ink Alzheimer's CDx Deal
  
• Merck Joins Pfizer to Develop Type 2 Diabetes Drug
  
• Merck Launches Up To $430M Diabetes Collaboration with Abide
  
• Merck & Co. Teams with Roche to Develop Companion Diagnostics for Cancer Therapy
  
• Merck & Co. and Roche Go Global with Marketing for Victrelis in HCV
  
• Merck & Co. Signs Up Abbott to Develop a Companion Diagnostic for Anticancer Candidate